The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular event reduction, limb viability, and symptom improvement. Hypertension, hyperlipidemia, and diabetes mellitus should all be controlled to recommended target levels, and smoking cessation is vital. Antiplatelet therapies, such as aspirin or clopidogrel, should be administered in all patients unless contraindicated. Whenever possible, patients who present with claudication should be offered a regimen comprised of both medical and exercise therapy, which often results in substantial improvement in symptoms. For patients presenting with more-advanced disease, such as acute limb ischemia, critical limb ischemia, and severely-limiting symptoms of ...
Objective: Peripheral arterial disease (PAD) is a global health issue associated with impaired funct...
Peripheral arterial disease (PAD) is a global health problem. The risk factors for developing PAD ha...
Craig M Walker,1,2 Frank T Bunch,3 Nick G Cavros,4 Eric J Dippel5 1Cardiovascular Institute of the ...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower limb arteries ...
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower limb arteries ...
The mainstay of therapy for peripheral arterial disease (PAD) consists ofatherosclerotic risk-factor...
An estimated 10 million people in the U.S. have symptomatic peripheral arterial disease (PAD); 20 to...
Endovascular treatments of peripheral artery disease: revascularization techniques for patients pres...
There has been much progress made in the management of peripheral arterial disease (PAD) in the past...
Peripheral arterial disease (PAD) affects about 27 million people in North America and Europe, accou...
Peripheral arterial disease (PAD) affects about 27 million people in North America and Europe, accou...
Peripheral arterial disease is estimated to affect more than 200 million people worldwide. Although ...
Objective: Peripheral arterial disease (PAD) is a global health issue associated with impaired funct...
Peripheral arterial disease (PAD) is a global health problem. The risk factors for developing PAD ha...
Craig M Walker,1,2 Frank T Bunch,3 Nick G Cavros,4 Eric J Dippel5 1Cardiovascular Institute of the ...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular...
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower limb arteries ...
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower limb arteries ...
The mainstay of therapy for peripheral arterial disease (PAD) consists ofatherosclerotic risk-factor...
An estimated 10 million people in the U.S. have symptomatic peripheral arterial disease (PAD); 20 to...
Endovascular treatments of peripheral artery disease: revascularization techniques for patients pres...
There has been much progress made in the management of peripheral arterial disease (PAD) in the past...
Peripheral arterial disease (PAD) affects about 27 million people in North America and Europe, accou...
Peripheral arterial disease (PAD) affects about 27 million people in North America and Europe, accou...
Peripheral arterial disease is estimated to affect more than 200 million people worldwide. Although ...
Objective: Peripheral arterial disease (PAD) is a global health issue associated with impaired funct...
Peripheral arterial disease (PAD) is a global health problem. The risk factors for developing PAD ha...
Craig M Walker,1,2 Frank T Bunch,3 Nick G Cavros,4 Eric J Dippel5 1Cardiovascular Institute of the ...